Answers are grounded in this paper and cite their sources.
Introduction: There is no effective therapy for amyotrophic lateral sclerosis (ALS).Safety and feasibility of intrathecal autologous stem cell injections in ALS patients is described.Methods: Fifteen ALS patients were enrolled.ALS functional rating scale revised (ALSFRS-R) was performed.They received subcutaneous filgrastim (600 µg) for 3 days.Then, CD34+ stem cells (150 ml) were bone marrow obtained and intrathechally injected.Patients were followed up for 1-year.Results: Eight females and 7 males were included (mean 47.6 years).Interval between onset and stem cell injection was 23.8 months.Mean ALSFRS-R at inclusion and six months was 33 and 32, respectively.Four patients died, mortality was associated to scores lower than 30 points at inclusion.Discussion: Intrathecal stem cell injection is safe, and well tolerated in ALS patients.Further studies with a greater number of patients are necessary to define the usefulness of intrathecal stem cell therapy in ALS patients.
No takes yet. Share an insight, caveat, or question.
Martínez et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: